

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE****Applicants Docket Number:**  
USAV2001/0002 US NP**Applicants:**

Craig P. Smith et al

**Serial No.**  
10/076,191**Filing Date:**  
February 14, 2002**Title of Invention:**  
METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Art Unit 1614, at 703-872-9306, on

Date of Deposit October 9, 2003Printed Name of Person Signing Certificate Generia WalkerSignature Generia Walker**Total Number of Pages Sent:** 3**Attorney:** Barbara E. Kurys**Group Art Unit:** 1614**Examiner:** Dwayne C. Jones**OFFICIAL****TO:** Mail Stop Art Unit 1614  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450**RECEIVED  
CENTRAL FAX CENTER****OCT 10 2003**

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |  |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal   |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____                                 |
| <input checked="" type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other _____   |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Response to Restriction Requirement</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal           |  |

**Receipt Confirmed:**

Signed \_\_\_\_\_

Dated \_\_\_\_\_

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
**NOTICE:** The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)